WebJan 7, 2009 · A therapeutic renaissance in the history of cancer therapy has been unfolding with the recent development of what has been termed the ‘novel agents’ for the treatment of multiple myeloma (MM). Less than a decade ago, MM therapy was in the doldrums and had been that way for decades. WebMar 24, 2024 · The frequency of HBV reactivation in myeloma patients has increased in the era of novel agents because bortezomib administration may be considered a possible risk factor for HBV reactivation [1, 2].

The next generation of novel therapies for the management of …

WebApr 14, 2024 · OM-301 has previously demonstrated efficacy against multiple myeloma in preclinical models. According to findings published in Blood, OM-301, although designed for p53-selective cells, may interact with Bcl-2, which effectively induces mitochondrial dysfunction and cell death regardless of TP53 status. 2 Overall, investigators concluded … WebOct 7, 2024 · The number of agents in multiple myeloma treatment regimens changed over the study period (Figure 1(B), ... In conclusion, with the approval of novel agents over the … jeff prevost survivor

[Novel agents in multiple myeloma treatment].

WebHowever, patients who relapse after treatment with these agents or are refractory to them represent an unmet need and highlight the necessity for the development of novel anti … Web1 day ago · OM-301 has received an orphan drug designation from the FDA for the treatment of patients with multiple myeloma, according to Oncolyze. 1. OM-301 is an investigational … WebNov 30, 2024 · Multiple myeloma (MM) is a plasma cell malignancy for which there is currently no cure. While treatment options for MM have expanded over the last two decades, all patients will eventually become resistant to current therapies. Thus, there is an urgent need for novel therapeutic strategies to treat MM. The isoprenoid biosynthetic pathway … jeff probst survivor 44